Brisbane biotech Vaxxas is developing a needle-free patch with the potential to transform vaccination globally. The high-density microarray patch (HD-MAP) features thousands of microprojections covered in tiny doses of vaccine that efficiently deliver vaccines to the skin, prompting an immune response comparable to a traditional needle and syringe while requiring a smaller dose.
Born from technology developed at UQ, Vaxxas established operations at TRI in 2015 to leverage its advanced infrastructure and industry support before expanding to a custom-built biomedical facility just over the river in 2023.
Since inception, Vaxxas has secured over A$300m in funding. Its latest private funding round will support late-stage clinical trials and manufacturing scale-up, positioning the company for its first commercial products and revenue generation from 2028.
5
Phase I clinical trials – Covid-19, influenza, measles & rubella
A$300m+
funding raised
130
scientist, engineers, quality, regulatory
